IMPACT Therapeutics inks US$488.3M Senaparib deal with Pharmanovia

CHINA— IMPACT Therapeutics has signed an exclusive licensing agreement with Pharmanovia worth up to €423.5m (US$488.3m), granting the pharmaceutical company rights to manufacture, develop, and commercialise senaparib across 66 countries.

Under the agreement, Pharmanovia will hold exclusive rights to senaparib for use as a maintenance monotherapy in adults with advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer.

IMPACT Therapeutics will receive an upfront payment as part of the agreement, alongside near-term regulatory milestone payments.

The company will also receive additional commercial milestone payments linked to the achievement of specified sales targets.

In addition, IMPACT Therapeutics is eligible for tiered royalties on net product sales, with rates reaching the mid-twenties percentage range.

The agreement will expand the potential availability of senaparib to all 27 European Union member states, as well as Australia, Iceland, Liechtenstein, New Zealand, Norway, Switzerland, and the UK.

It also covers several territories across the Middle East and North Africa.

Senaparib development and approvals

Senaparib is a poly(ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitor developed by IMPACT Therapeutics.

The companies said the partnership is intended to accelerate access to the treatment in the licensed markets following the necessary regulatory approvals.

IMPACT Therapeutics received approval from China’s National Medical Products Administration (NMPA) in January 2025 for senaparib as a first-line maintenance therapy for adults with advanced ovarian, fallopian tube, or primary peritoneal cancer.

The treatment was subsequently included in China’s National Reimbursement Drug List in December 2025, potentially broadening its availability to eligible patients through the country’s healthcare reimbursement system.

In Europe, the European Medicines Agency accepted a marketing authorisation application for senaparib in August 2025.

The application seeks approval for the treatment as a first-line maintenance therapy for adults with advanced ovarian cancer.

A regulatory decision on the European application is expected in the second half of 2026.

Pharmanovia partnership

Pharmanovia will bring its commercial infrastructure and experience in pharmaceutical product development and distribution to the partnership.

According to IMPACT Therapeutics, these capabilities will support the broader availability of senaparib across the territories covered by the licensing agreement.

The companies expect their collaboration to support the launch and commercialisation of senaparib in additional markets once the required regulatory approvals are secured.